Short-term efficacy of ORS formulation and propranolol regimen in children with POTS

Arch Pediatr. 2020 Aug;27(6):328-332. doi: 10.1016/j.arcped.2020.06.001. Epub 2020 Jul 7.

Abstract

Background: To evaluate the short-term effectiveness of reduced-osmolarity oral rehydration salt formulation (ORS) and propranolol in children diagnosed with postural orthostatic tachycardia syndrome (POTS) in head-up tilt testing (HUTT).

Methods: Children were admitted with symptoms of orthostatic intolerance (OI) occurring in a standing position and disappearing in the supine position. Patients with heart rate increments of ≥40bpm and symptoms of OI constituted the pediatric POTS group in HUTT. A total of 70 pediatric patients with POTS were included in the study. POTS patients were divided into two groups based on whether they were prescribed reduced-osmolarity ORS and propranolol or not. The study group comprised patients on a regimen of reduced-osmolarity ORS and propranolol (n=34), while the control group comprised patients who were not prescribed any medication (n=36). The frequency of symptoms and standardized symptom scores were analyzed before and after 3 months of treatment in both groups.

Results: The post-treatment frequency of syncopal attacks was significantly reduced in both groups (P<0.01 for both groups), but the post-treatment standardized symptom scores were significantly reduced in the pediatric study group compared with the control group (P<0.01).

Conclusion: The frequency of syncopal attacks was significantly reduced and the symptom scores for OI were improved in the study group. The improvement in OI symptom scores was better in the treatment group than in the control group. The control group symptoms persisted and caused extreme difficulty in their daily activities. In view of its clinical efficacy, we strongly advocate the use of combined treatment of reduced-osmolarity ORS and low-dose propranolol in pediatric patients with POTS.

Keywords: Oral rehydration salt; Orthostatic intolerance; Postural orthostatic tachycardia syndrome; Propranolol.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adrenergic beta-Antagonists* / therapeutic use
  • Child
  • Combined Modality Therapy
  • Electrolytes* / therapeutic use
  • Female
  • Fluid Therapy* / methods
  • Follow-Up Studies
  • Humans
  • Male
  • Postural Orthostatic Tachycardia Syndrome* / therapy
  • Propranolol* / therapeutic use
  • Prospective Studies
  • Rehydration Solutions* / therapeutic use
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Electrolytes
  • Propranolol
  • Rehydration Solutions